AcroCyte Therapeutics

🎗️ Ending Breast Cancer Awareness Month on a High Note 🎗️ The final stop in Acrocyte’s Hospital Speech Series was held at Shin Kong Wu Ho-Su Memorial Hospital (新光吳火獅紀念醫院)! Here’s a recap of the highlights from this impactful event:💡 🌟 Prof. Mark Pegram from Stanford opened by exploring the genetic twists driving breast cancer, showcasing Acrocyte’s R3CE® technology—a unique platform that turns CTCs into spheroids. Imagine using ex vivo biomarker staining on a patient’s bio-avatar as a precise weapon for tailored treatments! 🌟 Adding to the excitement, our CEO, Prof. Ying-Chih Chang, shared insights into the promising future of liquid biopsies and CTC cultivation, propelling us toward smarter, targeted cancer care. 🌟 Finally, Dr. Ruey-Kuen Hsieh discussed how traditional cancer treatments often rely on standardized protocols, limiting personalized care. With Acrocyte’s game-changing Onco-REAL™ platform, which provides real-time CTC monitoring via minimally invasive liquid biopsies, physicians gain invaluable insights. Biomarkers like HER2 and PD-L1 could help provide more therapeutic insights, and ex vivo drug testing helps identify the most effective therapies for each patient. We’d like to extend a huge thanks to the superintendent, the division chief, hosting team, and the dedicated doctors from Shin Kong Wu Ho-Su Memorial Hospital who joined us. Your contributions made this event even more special!🎉 At Acrocyte Therapeutics, we’re advancing cancer diagnostics and treatments through collaboration, innovation, and actionable data. Thank you to all who joined us! We look forward to welcoming you at future events as we shape the future of cancer care together. 💪 #AcrocyteTherapeutics #LiquidBiopsy #CancerDiagnostics #PrecisionMedicine #OncoREAL #R3CE #CTC

🌟 Empowering Precision Oncology with Acrocyte’s Innovations!🌟 Our recent seminar at Taipei Veterans General Hospital, TVGH (台北榮民總醫院)🏥 focused on advancements in breast cancer treatment and detection. We were privileged to invite collaborating physicians to share how technology has transformed their clinical experiences. Firstly, Prof. Mark Pegram from Stanford University opened the session with research on genetic mutations driving breast cancer. He highlighted Acrocyte’s R3CE® platform, which cultures tissues into organoids and circulating tumor cells (CTCs) into spheroids. 💡 This groundbreaking technology enables ex vivo biomarker staining, empowering physicians with critical data to guide tailored drug or cell therapy selection. Additionally, our CEO, Prof. Ying-Chih Chang delved into the potential of liquid biopsies and circulating tumor cell cultivation 💉, offering a new frontier in real-time cancer prognosis and drug monitoring for personalized care. Lastly, Dr. Chun-Yu Liu, an oncology specialist from TVGH, shared his experience using Onco-REAL™ in clinical practice. 💊 His insights underscored how the platform supports treatment decisions and provides crucial information to optimize patient care in breast cancer treatment. We’re grateful for the enthusiastic feedback and contributions from our esteemed collaborators at TVGH. Thank you to everyone who joined us and advanced the dialogue in precision oncology! 🎉 #AcrocyteTherapeutics #LiquidBiopsy #CancerDiagnostics #PrecisionMedicine #OncoREAL #R3CE #CTC #BreastCancer

Last Tuesday, October 29th, we had the privilege of hosting a seminar at Far Eastern Hospital (亞東紀念醫院)🏥 focused on the groundbreaking potential of liquid biopsy in cancer diagnostics.💉 The session was opened by Stanford University’s Prof. Mark Pegram, who shared pioneering research on diagnostic and therapeutic approaches within the tumor microenvironment. Prof. Pegram highlighted how AcroCyte’s proprietary R3CE® platform enables the culture of circulating tumor cells into organoids, providing critical insights for physicians through biomarker staining, whole exome sequencing (WES), RNA sequencing, and more. The possibilities are truly transformative! 💡 Our CEO, Prof. Ying-Chih Chang, followed with an in-depth exploration of CTC application, Onco-REAL™, and its crucial role in prognostic evaluation and drug monitoring 💊, emphasizing the immense potential of these insights for advancing personalized cancer care.💪🏻 The event concluded with a dynamic Q&A, where physicians exchanged perspectives and discussed the future impact of these innovations on patient care. At AcroCyte Therapeutics, we are committed to pushing the boundaries of cancer diagnostics and treatment and fostering collaborative breakthroughs in precision oncology. A heartfelt thank you to everyone who joined and contributed to this impactful conversation!🎉 #AcroCyteTherapeutics #LiquidBiopsy #CancerDiagnostics #PrecisionMedicine #R3CE #CTC #OncoREAL™

⭐Inspiring Insights from the Master Forum⭐ AcroCyte Therapeutics was honored to attend the Master Forum at National Taiwan University School of Medicine. 🏫 The event began with an opening address by Dean Yen-Hsuan Ni, followed by an inspiring introduction by Prof. Ying-Chih Chang on the exciting global growth opportunities available through the Taiwan Science and Technology Hub program.🎓 We also gained invaluable insights from two pioneers in cancer research, Prof. Mark Pegram from Stanford University and President Mien-Chie Hung from China Medical University. Prof. Pegram shared the journey of HER2 from discovery to clinical impact, highlighting the path of all truth: 1) Dismissal, 2) Opposition, and 3) Those who opposed the most claim credit for discovery. His takeaway? Embrace the unexpected—it may be the spark for groundbreaking discoveries.✨ This insight strongly resonates with us, as we know unexpected results could hold the key to unveiling new truths while we work on advancing the next generation of liquid biopsy diagnostics.💉 President Hung, on the other hand, underscored Taiwan’s role as a “Technology Island” filled with young, brilliant scientists poised for impact. He called on the next generation to push forward in life sciences. At AcroCyte, we welcome scientists and professionals who bring fresh perspectives to drive precision oncology with us. Last but not least, if you're interested in taking your next step abroad with the Taiwan Science and Technology Hub Program, please visit: https://lnkd.in/grbnZhVH 🎗️ Join us on this journey to shape a healthier tomorrow! 🎗️ #BreastCancerAwareness #PrecisionOncology #Innovation #MarkPegram #MienChieHung #LiquidBiopsy #R3CE #TaiwanSTHub

🎗️ Breast Cancer Awareness Month with AcroCyte Events 🎗️ AcroCyte Therapeutics invites you to an exclusive series of events featuring Prof. Mark Pegram from Stanford, a global pioneer in breast cancer research.   ⭐【Master Forum】⭐ 10/28 (Mon) 13:30-16:00 at Room 101, National Taiwan University School of Medicine Ever wondered about the journey that led to Herceptin 💉, the first antibody drug for breast cancer? Or the visionary turning groundbreaking research 🔬 into life-saving treatments? 💊 Let's sit with the giants and hear their stories about their experiences, challenges, and triumphs. 🎉 🡪 Register Now: https://lnkd.in/gpNYkydN   🏥【Hospital Seminars】🏥 Join us for an exciting series of seminar talks at three leading hospitals in Taipei! We’ll be covering the latest advances in precision oncology, liquid biopsy technology, and exciting case sharing. We hope to see you there! 🧫 10/29 (Tues) 07:30-09:10 at 2F Radiation Oncology Meeting Room, Far Eastern Hospital 🧫 10/29 (Tues) 14:30-17:00 at 1F Chang Ching Building Nursing Meeting Hall (長青樓護理館), Taipei Veteran General Hospital 🧫 10/30 (Wed) 12:00-16:30 at B1 Grand Meeting Room, B3 Conference Room, Shing Kong Hospital (Walk-in conference meeting. Registration not required. ) #AcroCyte #PrecisionOncology #LiquidBiopsy #BreastCancer #1CelltoSaveLives

👨💼 Dr. Yao-Ting Wang (王耀庭 博士), Chairman of AcroCyte Therapeutics Inc., has successfully transformed academic research into commercial achievements through his exceptional leadership and innovative spirit. His entrepreneurial journey is filled with challenges and accomplishments, from starting a business while pursuing his Ph.D. to successfully entering TSMC's supply chain, and founding multiple companies that went public on NASDAQ. Dr. Wang's story has inspired countless scholars and professionals aspiring to entrepreneurship. 🚀   In terms of business philosophy, Dr. Wang firmly believes that "a product is truly a product if someone is willing to pay for it." 🌟 This pragmatic approach has led to significant achievements in both entrepreneurship and investment. 🤝 Today, under his leadership, #AcroCyte is at the forefront of 3D cell culture and organoid technology, particularly with its #R3CE technology, showcasing the immense potential of future biomedical advancements.   To learn more about Dr. Wang's entrepreneurial story and his investment philosophy in Taiwanese startups, listen to the podcast or read this article: 👉 阿榕伯胡說科技: 曾拯救摩爾定律的史丹佛連續創業家，他為什麼開始投資台灣教授？feat. 王耀庭 https://lnkd.in/giSuRn_F 👉 30多歲創業就讓台積買單、打造EDA市值最高公司　王耀庭：找客戶先攻下大公司. https://lnkd.in/gpxP_nXD #Entrepreneurship #Biotechnology #3DCellCulture #Organoid #TaiwanStartups #YaoTingWang #AcroCyte #R3CE

AcroCyte is thrilled to share that we recently had the honor of hosting Prof. Chi-Huey Wong (翁啟惠院士). 👏 This warm visit was a pivotal moment for our company as we showcased our innovative work. 🌟 Prof. Wong’s insightful feedback and endorsement were incredibly encouraging, reinforcing our belief in our promising path and motivating us to push the boundaries even further. 🤝🏻 We're incredibly grateful to Prof. Wong for his time and invaluable input. His support has fueled our excitement for the future and the opportunities ahead as we continue to advance our mission and make a positive impact. 💪 👉 Stay tuned for more updates on our journey! #AcroCyte #1CellToSaveALife #R3CE #OncoREAL #Innovation

We are thrilled to announce the successful conclusion of our presentation on the innovative R3CE® technology and our new service, Onco-REAL™, for clinical applications in precision oncology! 🎉    🔍 Here's a snapshot of what we presented:    🚀R3CE® Plates:   Our core technology, R3CE® (Rapid, Reproducible, and Rare Cell Expansion) features:  ✅ growth of any cell type  ✅ into 3D cell culture  ✅ within 2 weeks  ✅ feasible for extremely rare cells  ✅ with no animal or bio-derived components    🚀Onco-REAL™ platform:   With the help of R3CE® technology for enhancing the growth of Circulating Tumor Cells (CTCs), we generate more reliable CTC count data, facilitating early cancer detection through precise prognosis and monitoring. The ability to culture these cells allows us to conduct comprehensive drug tests, providing targeted recommendations for drug selection and ensuring medications are administered at their most effective intervals.    Interested? Talk to us about our technology and applications at info@acrocyte.com or reach out to us at AcroCyte Therapeutics. A heartfelt thank you to all participating hospitals including #ChangGungMemorialHospital, #FarEasternMemorialHospital, #NationalTaiwanUniversityHospital, #PojenGeneralHospital, #ShingKongHospital, #VeteransGeneralHospital, #TaiwanAdventistHospital, #TaipeiShowChwanHospital and #TzuChiHospital! 🏥 #AcroCyte #R3CE #3DCellCulture #PrecisionMedicine #CTC #CirculatingTumorCell #Organoid #Cancer #DrugSelection

It is a wrap! We enjoyed our inaugural visit to US Bio Conference, where we had the pleasure of meeting professionals and establishing connections from around the globe. Our gratitude goes out to everyone who visited our booth to inquire about our R3CE 3D cell culture plate and to share ideas and knowledge. The myriad of innovations in the biotech industry worldwide was truly inspiring, and we are excited about the potential impact on lives. AcroCyte is honored to be a part of this dynamic field! If you would like to connect and learn more about AcroCyte and our R3CE plate, please do not hesitate to contact our Business Development Manager Jaffer Yang jaffer.yang@acrocyte.com or our CEO Ying Chang. #USBIO2024 #BIO2024

🌟 Exciting News! 🌟  We're happy to announce the formal launch of our R3CE platform at the upcoming Bio2024 conference in San Diego, taking place from June 3rd to 6th. 🎉 If you are coming to Bio2024, please Visit Booth and Talks: Our passionate Acrocyte Therapeutics team will be ready to showcase R3CE and discuss its transformative potential. Plus, you can get a free try if you enter our simple polls.  Additionally, we will present our innovations at these 2 events. 1. Taiwan Smart Health Gala 📅Date: June 3 🕒Time: 9:00-12:30 🌐 Location: San Diego Ballroom B 2. Start-Up Stadium at BIO 2024 📅Date: June 5 🕒Time: 14:00-16:00 🌐 Location: San Diego Convention Center We are proud to be selected as one of the finalists of the convention. Come and cheer for our hard-working, energetic Acrocyters!  Contact Us: Can’t make it to the conference? No worries! Reach out to us via email at info@acrocyte.com. Let’s collaborate and revolutionize cell culture practices together! ✨ World, meet R3CE A game-changing 3D culture platform provides researchers with the means to delve deep into the realms of cancer research, clinical treatments, and drug discovery. R3CE, which stands for “rapid, reproducible, rare cell expansion,” represents a paradigm shift in 3D cell culture. Unlike traditional methods, our scaffold-free, optically transparent approach allows cells to self-assemble into intricate 3D structures without the need for external support matrices. 🧪🔬 Here's why R3CE makes 2D cell culture and animal models forever obsolete-  Transparent and Self-Proliferative: With R3CE, you’ll witness cells thriving in their natural environment. The transparency and semi-attached natures enable real-time observation, making it ideal for studying cell behavior, interactions, and responses to therapies. Rare Cell Expansion: Whether you’re working with rare cell populations or aiming to expand specific cell types, R3CE empowers you. Say goodbye to laborious and inconsistent 3D culture products! Embrace 3D Models: If you’re a believer in the power of 3D models over flat monolayers, our platform is tailor-made for you. Unlike 2D cell cultures and animal models, offering a realistic, personalized, cost-effective, scalable, and ethical alternative for clinical research and precision medicine! Watch R3CE in action! www.acrocyte.com